Archana
Archana Bommi-Reddy, Boston, MA US
Patent application number | Description | Published |
---|---|---|
20100016434 | Inhibitors of Egln3 Activity for the Treatment of Neurodegenerative Disorders - The present invention provides methods for preventing or reducing neuronal apoptosis, particularly wherein the apoptosis is associated with a neurodegenerative disorder in a subject. | 01-21-2010 |
20110275697 | REGULATION OF CYCLIN D - The present invention provides methods for modulating the level or activity of cyclin D by inhibiting EGLN2 expression or activity. The methods are particularly useful for treating or preventing a disorder associated with elevated cyclin D levels or activity, such as cancer. | 11-10-2011 |
Archana Chugh, Lethbridge CA
Patent application number | Description | Published |
---|---|---|
20110035836 | NANOCARRIER BASED PLANT TRANSFECTION AND TRANSDUCTION - The present invention provides a novel method for the transduction and/or transfection of plant cells. Cell-penetrating peptides (CPPs) have been successfully employed as nanocarriers to deliver proteins and oligonucleotides to single plant cell microspores as well as multi-cellular zygotic embryos. The efficiency of CPP internalization and further delivery of a macromolecular cargo comprising a protein and/or an oligonucleotide can be enhanced by permeabilization of the zygotic embryos. | 02-10-2011 |
20140182012 | NANOCARRIER BASED PLANT TRANSFECTION AND TRANSDUCTION - The present invention provides a novel method for the transduction and/or transfection of plant cells. Cell-penetrating peptides (CPPs) have been successfully employed as nanocarriers to deliver proteins and oligonucleotides to single plant cell microspores as well as multi-cellular zygotic embryos. The efficiency of CPP internalization and further delivery of a macromolecular cargo comprising a protein and/or an oligonucleotide can be enhanced by permeabilization of the zygotic embryos. | 06-26-2014 |
Archana Dwivedi, London GB
Patent application number | Description | Published |
---|---|---|
20110027350 | GLYCOPOLYSIALYLATION OF NON-BLOOD COAGULATION PROTEINS - A water soluble polymer, in particular polysialic acid (PSA) or a modified PSA (mPSA), is conjugated to an oxidized carbohydrate moiety of a glycoprotein other than a blood coagulation protein or to a ganglioside or drug delivery system by contacting the oxidized carbohydrate moiety with the water soluble polymer, wherein said water soluble polymer contains an aminooxy group and an oxime linkage is formed between the oxidized carbohydrate moiety and the aminooxy group on the water soluble polymer or wherein said water soluble polymer contains a hydrazide group and a hydrazone linkage is formed between the oxidized carbohydrate moiety and the hydrazide group on the water soluble polymer. Conjugates of aminooxy- or hydrazide-water soluble polymer, such as PSA and mPSA, are thus obtained in which the PSA or mPSA is attached via a carbohydrate moiety. | 02-03-2011 |
Archana Gadadhar, Chicago, IL US
Patent application number | Description | Published |
---|---|---|
20110129450 | METHOD OF PROMOTING NEUROGENESIS BY MODULATING SECRETASE ACTIVITIES - This invention provides methods and reagents for promoting neurogenesis, by modulating neural stem cell proliferation and differentiation. Particularly, this invention provides methods and reagents for promoting neurogenesis in a patient's central nervous system where the patient suffers from an aging-related neurodegenerative disease. Specifically, the invention provides methods for promoting neurogenesis comprising modulating the α and/or γ-secretase activities. | 06-02-2011 |
Archana Gangakhedkar, San Jose, CA US
Patent application number | Description | Published |
---|---|---|
20090192225 | Acyloxyalkyl Carbamate Prodrugs of Alpha-Amino Acids, Methods of Synthesis and Use - Acyloxyalkyl carbamate prodrugs of α-amino acids, pharmaceutical compositions thereof, methods of making acyloxyalkyl carbamate prodrugs of α-amino acids and methods of using acyloxyalkyl carbamate prodrugs of α-amino acids, and pharmaceutical compositions thereof to treat a disease are disclosed. Acyloxyalkyl carbamate prodrugs of α-amino acids suitable for oral administration using sustained release dosage forms are also disclosed. | 07-30-2009 |
20100048651 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE - Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed. | 02-25-2010 |
20120095003 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF - Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed. | 04-19-2012 |
20120157523 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE - Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed. | 06-21-2012 |
20140329818 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF - Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed. | 11-06-2014 |
20150197486 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF - Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed. | 07-16-2015 |
Archana Gautaum, Indianapolis, IN US
Patent application number | Description | Published |
---|---|---|
20160000387 | BODY SUPPORT WITH ANATOMICAL APERTURE - A body support comprising a support surface with at least one anatomical aperture configured to allow at least one appendage to protrude through the at least one anatomical aperture for a medical treatment is disclosed. Additionally, a method for positioning a user on the body support is also disclosed. | 01-07-2016 |
Archana Gupta, Uttar Pradesh IN
Patent application number | Description | Published |
---|---|---|
20130317057 | ALDOSTERONE SYNTHASE INHIBITORS - The invention involves compounds of structural Formula (I) and the pharmaceutically acceptable salts thereof. The compounds of the invention are effective at selectively inhibiting CYP11B2, and are therefore useful for the treatment or prophylaxis of disorders that are associated with elevated aldosterone levels, including, but not limited to, hypertension and heart failure. | 11-28-2013 |
Archana Jalota-Badhwar, Pune IN
Patent application number | Description | Published |
---|---|---|
20110046342 | TUMOR SUPPRESSOR ACTIVATING POLYPEPTIDES AND USES THEREOF - Chimeric tumor suppressor activating peptides derived from matrix attachment region binding protein (MARBP) SMARI unique in their sequence comprising a arginine rich motif flanked by serine residues wherein from the stretch of four consecutive serine residues the first serine residue gets phosphorylated by the protein kinase C family of serine threonine kinases being indispensable for its functionality, the phosphorylation being directly correlated to the phosphorylation of p53 at serine 15 residue thereby stabilizing it, wherein the peptide activates p53 by modifying it post translationally which allow phosphorylation and translocation of p53 to the nucleus. | 02-24-2011 |
Archana P.r., Kochi IN
Patent application number | Description | Published |
---|---|---|
20140363514 | CORE-SHELL PARTICLE FORMULATION FOR DELIVERING MULTIPLE THERAPEUTIC AGENTS - A core-shell particle formulation for delivering multiple therapeutic agents is disclosed. More particularly, core-shell particle formulation configured to independently release therapeutic agents from the core and the shell. Moreover, the core-shell particle bearing therapeutic agents enables treatment against the diseases such as cancer, inflammatory and auto-immune diseases. | 12-11-2014 |
Archana P.retnakumari, Kochi IN
Patent application number | Description | Published |
---|---|---|
20150209288 | CORE-SHELL PARTICLE FORMULATION FOR DELIVERING MULTIPLE THERAPEUTIC AGENTS - A core-shell particle formulation for delivering multiple therapeutic agents is disclosed. More particularly, the formulation comprising protein-protein core-shell particle configured to independently release therapeutic agents from the core and the shell. Moreover, the core-shell particle bearing therapeutic agents enable treatment against the diseases such as cancer, inflammatory and auto-immune diseases. | 07-30-2015 |
Archana Somachudan, Austin, TX US
Patent application number | Description | Published |
---|---|---|
20140132291 | SCALABLE BUILT-IN SELF TEST (BIST) ARCHITECTURE - A circuit with built-in self test (BIST) capability includes a master BIST controller, a plurality of slave BIST controllers, and a collector. The master BIS controller issues test instructions in response to a master resume input signal. The plurality of slave BIST controllers is coupled to the master BIST controller. Each slave BIST controller is adapted to perform a test on a functional circuit in response to a test instruction and to provide a resume signal at a conclusion of the test. The collector receives a corresponding resume signal from each of the multiple slave BIST controllers after the master BIST controller issues the test instruction, and subsequently provides the master resume signal in response to an activation of all of the corresponding resume signals. | 05-15-2014 |
20140173345 | MEMORY BIT MBIST ARCHITECTURE FOR PARALLEL MASTER AND SLAVE EXECUTION - A scalable, reconfigurable Memory Built-In Self-Test (MBIST) architecture for a semiconductor device, such as a multiprocessor, having a Master and one or more Slave MBIST controllers is described. The MBIST architecture includes a plurality of MBISTDP interfaces connected in a ring with the Master MBIST controller. Each MBISTDP interface connects to at least one Slave controller for forwarding test information streamed to it from the Master MBIST controller over the ring. Test information includes test data, address, and MBIST test commands. Each MBISTDP interface forwards the information to the Slave controller attached thereto and to the next MBISTDP interface on the ring. Test result data is sent back to the Master MBIST controller from the MBISTDP interfaces over the ring. | 06-19-2014 |